These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. The REDUCE trial: chemoprevention in prostate cancer using a dual 5alpha-reductase inhibitor, dutasteride. Musquera M; Fleshner NE; Finelli A; Zlotta AR Expert Rev Anticancer Ther; 2008 Jul; 8(7):1073-9. PubMed ID: 18588452 [TBL] [Abstract][Full Text] [Related]
3. Reduction in the risk of prostate cancer: future directions after the Prostate Cancer Prevention Trial. Crawford ED; Andriole GL; Marberger M; Rittmaster RS Urology; 2010 Mar; 75(3):502-9. PubMed ID: 20035983 [TBL] [Abstract][Full Text] [Related]
4. When is active surveillance the appropriate treatment for prostate cancer? Albertsen PC Acta Oncol; 2011 Jun; 50 Suppl 1():120-6. PubMed ID: 21604952 [TBL] [Abstract][Full Text] [Related]
5. Chemoprevention of prostate cancer: agents and study designs. Thompson IM J Urol; 2007 Sep; 178(3 Pt 2):S9-S13. PubMed ID: 17644117 [TBL] [Abstract][Full Text] [Related]
6. Pharmacological approaches to reducing the risk of prostate cancer. Rittmaster RS; Fleshner NE; Thompson IM Eur Urol; 2009 May; 55(5):1064-73. PubMed ID: 19200641 [TBL] [Abstract][Full Text] [Related]
7. Reducing the "risk" of chemoprevention: defining and targeting high risk--2005 AACR Cancer Research and Prevention Foundation Award Lecture. Lippman SM; Lee JJ Cancer Res; 2006 Mar; 66(6):2893-903. PubMed ID: 16540634 [TBL] [Abstract][Full Text] [Related]
8. Chemoprevention of prostate cancer. Stephenson AJ; Abouassaly R; Klein EA Urol Clin North Am; 2010 Feb; 37(1):11-21, Table of Contents. PubMed ID: 20152515 [TBL] [Abstract][Full Text] [Related]
9. Can we prevent prostate cancer? Rationale and current status of prostate cancer chemoprevention. Fujimoto N; Chang C; Nomura M; Matsumoto T Urol Int; 2005; 74(4):289-97. PubMed ID: 15897691 [TBL] [Abstract][Full Text] [Related]
10. 5alpha-reductase inhibitors in benign prostatic hyperplasia and prostate cancer risk reduction. Rittmaster RS Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):389-402. PubMed ID: 18471794 [TBL] [Abstract][Full Text] [Related]
11. Overview of pivotal studies for prostate cancer risk reduction, past and present. Andriole GL Urology; 2009 May; 73(5 Suppl):S36-43. PubMed ID: 19375625 [TBL] [Abstract][Full Text] [Related]
12. Chemoprevention of prostate cancer. Thompson IM; Tangen CM; Goodman PJ; Lucia MS; Klein EA J Urol; 2009 Aug; 182(2):499-507; discussion 508. PubMed ID: 19524966 [TBL] [Abstract][Full Text] [Related]
14. Chemoprevention of prostate cancer. Klein EA Crit Rev Oncol Hematol; 2005 Apr; 54(1):1-10. PubMed ID: 15780904 [TBL] [Abstract][Full Text] [Related]
15. Dutasteride: novel milestones in prostate cancer chemoprevention. Rove KO; Crawford ED Drugs Today (Barc); 2011 Feb; 47(2):135-44. PubMed ID: 21431101 [TBL] [Abstract][Full Text] [Related]
16. Open to debate. The motion: prevention of prostate cancer with a 5alpha-reductase inhibitor is feasible. Roehrborn CG; Lotan Y; Tubaro A; de Nunzio C Eur Urol; 2006 Feb; 49(2):396-400. PubMed ID: 16455190 [No Abstract] [Full Text] [Related]
17. Consequences of switching 5alpha-reductase inhibitors on prostate specific antigen velocity. Helfand BT; Blackwell RH; McVary KT J Urol; 2010 Jul; 184(1):218-23. PubMed ID: 20483154 [TBL] [Abstract][Full Text] [Related]
18. Biology and natural history of prostate cancer and the role of chemoprevention. Rosenberg MT; Froehner M; Albala D; Miner MM Int J Clin Pract; 2010 Dec; 64(13):1746-53. PubMed ID: 21070525 [TBL] [Abstract][Full Text] [Related]
19. Chemoprevention of prostate cancer by diet-derived antioxidant agents and hormonal manipulation (Review). Pathak SK; Sharma RA; Mellon JK Int J Oncol; 2003 Jan; 22(1):5-13. PubMed ID: 12469179 [TBL] [Abstract][Full Text] [Related]
20. The effects of 5alpha-reductase inhibitors on the natural history, detection and grading of prostate cancer: current state of knowledge. Andriole G; Bostwick D; Civantos F; Epstein J; Lucia MS; McConnell J; Roehrborn CG J Urol; 2005 Dec; 174(6):2098-104. PubMed ID: 16280736 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]